Find out more about us and our portfolio companies

The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform, EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties.

LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales.

Fast Track Designation (FTD) recognizes NOUS-209’s potential to address a serious condition with significant unmet medical need in Lynch Syndrome (LS) carriers.